Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zervimesine - Cognition Therapeutics

Next Previous
Drug Profile

Zervimesine - Cognition Therapeutics

Alternative Names: CT-1812; Elayta

Latest Information Update: 16 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cognition Therapeutics
  • Developer Alzheimers Clinical Trials Consortium; Cognition Therapeutics
  • Class Antidementias; Antiparkinsonians; Eye disorder therapies; Isoindoles; Neuroprotectants; Nootropics; Phenols; Small molecules; Sulfones
  • Mechanism of Action Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Dry age-related macular degeneration; Lewy body disease
  • No development reported Parkinson's disease
  • Discontinued Cognition disorders

Most Recent Events

  • 24 Jun 2026 Cognition Therapeutics plans a phase III registrational study for Lewy body disease (Adjunctive treatment) in the US (PO) in mid 2027
  • 24 Jun 2026 Cognition Therapeutics completed meeting with the US FDA Division of Psychiatry for registrational plan in Lewy body disease
  • 24 Jun 2026 Efficacy data from a phase II SHIMMER trial in Dementia released by Cognition Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top